Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS toward a Phase 2 clinical trial while also generating commercial revenue from its unbuzzd product, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast. The company is pursuing a dual strategy that combines clinical-stage pharmaceutical development with commercial sales targeting neurodegenerative, metabolic and alcohol-misuse conditions.

Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Durkacz said the company has filed an investigational new drug application for a Phase 2 trial, which could mark the candidate’s first administration to human MS patients. The drug is intended to address mobility damage associated with MS, which remains a significant unmet need for patients, and its progress highlights the kind of regulatory step that often separates early research from later-stage clinical testing.

In addition to its clinical pipeline, Quantum BioPharma is producing revenue through unbuzzd, a commercially available product intended to accelerate alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.84% ownership stake as of March 31, 2026, according to unbuzzd.com. The agreement provides for royalty payments equal to 7% of sales until Quantum BioPharma receives $250 million, after which the royalty rate falls to 3% in perpetuity. Quantum BioPharma also retains 100% of the rights to develop pharmaceutical and medical formulations of the product.

Durkacz said that combining clinical-stage assets with commercial products offers a balanced risk profile and near-term revenue potential. He added that the company’s focus on neurodegenerative disorders, metabolic conditions and alcohol misuse aligns with large market opportunities, while also giving the firm multiple ways to advance its portfolio without relying on a single development program.

Quantum BioPharma said its strategy reflects a commitment to building a portfolio of innovative therapies. More information on the podcast is available at and company updates can be found in its newsroom at

The company cautioned that forward-looking statements involve risks and uncertainties, including those described in its SEC filings, and advised against undue reliance on such statements.